These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1629 related articles for article (PubMed ID: 11252954)

  • 1. Untangling the ErbB signalling network.
    Yarden Y; Sliwkowski MX
    Nat Rev Mol Cell Biol; 2001 Feb; 2(2):127-37. PubMed ID: 11252954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy.
    Friedländer E; Arndt-Jovin DJ; Nagy P; Jovin TM; Szöllosi J; Vereb G
    Cytometry A; 2005 Oct; 67(2):161-71. PubMed ID: 16163699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB; Hynes NE; Lane HA
    Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.
    Nagy P; Jenei A; Damjanovich S; Jovin TM; Szölôsi J
    Pathol Oncol Res; 1999; 5(4):255-71. PubMed ID: 10607920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin.
    Anastasi S; Sala G; Huiping C; Caprini E; Russo G; Iacovelli S; Lucini F; Ingvarsson S; Segatto O
    Oncogene; 2005 Jun; 24(28):4540-8. PubMed ID: 15856022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.
    Kirouac DC; Du JY; Lahdenranta J; Overland R; Yarar D; Paragas V; Pace E; McDonagh CF; Nielsen UB; Onsum MD
    Sci Signal; 2013 Aug; 6(288):ra68. PubMed ID: 23943608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart.
    Schneider JW; Chang AY; Rocco TP
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):18-26. PubMed ID: 11706392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors.
    Zhan L; Xiang B; Muthuswamy SK
    Cancer Res; 2006 May; 66(10):5201-8. PubMed ID: 16707444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ErbB/HER receptor protein-tyrosine kinases and cancer.
    Roskoski R
    Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
    Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
    Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium.
    Fuller SJ; Sivarajah K; Sugden PH
    J Mol Cell Cardiol; 2008 May; 44(5):831-54. PubMed ID: 18430438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells.
    Shell SA; Lyass L; Trusk PB; Pry KJ; Wappel RL; Bacus SS
    Cell Cycle; 2008 Jun; 7(12):1769-75. PubMed ID: 18594201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
    Chan CT; Metz MZ; Kane SE
    Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.
    Kennedy SP; Han JZR; Portman N; Nobis M; Hastings JF; Murphy KJ; Latham SL; Cadell AL; Miladinovic D; Marriott GR; O'Donnell YEI; Shearer RF; Williams JT; Munoz AG; Cox TR; Watkins DN; Saunders DN; Timpson P; Lim E; Kolch W; Croucher DR
    Breast Cancer Res; 2019 Mar; 21(1):43. PubMed ID: 30898150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer.
    Järvinen TA; Liu ET
    Curr Cancer Drug Targets; 2006 Nov; 6(7):579-602. PubMed ID: 17100565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes.
    Stoll SW; Kansra S; Peshick S; Fry DW; Leopold WR; Wiesen JF; Sibilia M; Zhang T; Werb Z; Derynck R; Wagner EF; Elder JT
    Neoplasia; 2001; 3(4):339-50. PubMed ID: 11571634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 82.